The Gavathiotis laboratory focuses on chemical and structural biology to elucidate and target protein interaction mechanisms of deregulated signaling pathways in cancer and other diseases. Our ultimate goal is to translate structural and mechanistic insights into novel pharmacologic strategies and develop therapeutics that can lead to
cures. To achieve our goal, we take an interdisciplinary approach using chemical synthesis, structure-based design, structural biology, biochemistry, cellular and in vivo pharmacology.
Dr. Gavathiotis was awarded a $1.73 million R01 grant to investigate a novel pharmacological strategy for killing cancer cells by activating the protein BAX—a key player in apoptosis, the process by which cells self-destruct. BAX performs its deadly work by puncturing the membranes of mitochondria, the energy power plants inside cells. See more
The Innovation core is funded through a National Institute of Aging PO1 Award led by Dr. Ana Maria Cuervo. Our lab will provide expertise, reagents, analysis and interpretation using chemical and structural biology technologies with the aim to assist the development of pharmacological modulation of key components of autophagy in aging.
Onyi received a prestigious F31 Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship by NIH. Congrats Onyi!
Denis Reyna was accepted to the Einstein Graduate Program in Biomedical Sciences. Congrats Denis!
Dr. Evripidis Gavathiotis has been selected as the 2013 Sinsheimer Scholar Award recipient by the Alexandrine and Alexander L. Sinsheimer Foundation. The foundation provides "funding to individuals who demonstrate potential for making major contributions with respect to the prevention or cure of human disease."
Tom receives the "best poster award" in the Annual Chemical Biology Symposium organized by the New York Academy of Sciences!
The Kimmel Scholar Awards were created to advance the careers of gifted, young scientists involved in cancer research. Those selected are chosen for demonstrating the greatest promise and innovation in their work, must be in the early stages of their research career, and have not progressed far enough to have received major grants from the National Cancer Institute or other funding sources.
A new paper from Anguiano et al. in Nature Chemical Biology demonstrates a structure-based design of RARα antagonists that leads to compounds that can selectively upregulate chaperone-mediated autophagy (CMA), yielding the first chemically tractable target for regulating CMA in cells!
The Foundation funds innovative clinical or basic science research that will lead to novel therapeutic approaches that could replace, or be used in combination with existing effective therapies and improve the quality of life of patients with leukemia or lymphoma. Since its inception, Gabrielle's Angel Foundation has proudly distributed nearly $20 million in Medical Research Awards to more than 100 of the nation's leading junior investigators.